Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01826916 | EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema | PHASE2 | COMPLETED | 77 | — | — | Nov 1, 2003 | Jan 1, 2006 | May 18, 2021 | - | — |
successful outcome is defined as attack resolution begun within 4 hrs after treatment and maintained for 24 hours
partial response is defined as an initial response to dosing followed by a relapse within 4 to 24 hours
| Arm | Type | Description |
|---|---|---|
| 5mg/m2 DX-88 IV | EXPERIMENTAL | 5mg/m2 DX-88 (ecallantide)administered intravenously |
| 10mg/m2 DX-88 IV | EXPERIMENTAL | 10mg/m2 DX-88(ecallantide)administered intravenously |
| 20mg/m2 DX-88 IV | EXPERIMENTAL | 20mg/m2 DX-88 (ecallantide) administered intravenously |
| 30 mg DX-88 SC | EXPERIMENTAL | 30mg DX-88(ecallantide)administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| DX-88 (ecallantide) | DRUG | solution for injection 10 mg/mL |
Inclusion Criteria: * 10 years of age or older * Documented diagnosis of HAE (Type I or II) * Patient reported to a study site no later than 4 hours following patient recognition of the onset of the attack * Willing and able to give informed consent Exclusion Criteria: * Patients with a serious i...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. | NTLA | 3 | PHASE3 | NTLA-2002, Normal Saline Administration, Biological NTLA-2002 |
| BioCryst Pharmaceuticals, Inc. | BCRX | 2 | PHASE3 | Berotralstat, berotralstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Donidalorsen |
| KalVista Pharmaceuticals, Inc. | KALV | 1 | PHASE3 | KVD900, Drug: KVD900 |
| Pharvaris N.V. | PHVS | 1 | PHASE2 | deucrictibant |
| BioMarin Pharmaceutical Inc. | BMRN | 1 | PHASE1 | Dose 1 of BMN 331 |
| Astria Therapeutics, Inc. | ATXS | 1 | PHASE2 | STAR-0215 |